Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + pertussis vaccine + poliomyelitis vaccine + haemophilus influenzae type b conjugate vaccine + meningococcal (groups A, C, Y, W) conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the concomitant administration of Sanofi's quadrivalent meningococcal conjugate vaccine (MenACYW-TT, brand name MenQuadfi) and their pentavalent pediatric vaccine (DTaP-IPV-Hib, brand name Pentaxim or Pentavac). MenQuadfi is a conjugate vaccine containing capsular polysaccharides from Neisseria meningitidis serogroups A, C, Y, and W-135, each covalently linked to a tetanus toxoid carrier protein. It is indicated for active immunization to prevent invasive meningococcal disease. Pentaxim is a combination vaccine that provides protection against diphtheria, tetanus, pertussis, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b. The co-administration of these vaccines is a standard practice in pediatric immunization schedules and has been extensively studied in clinical trials (e.g., MET33, MET57) to confirm that the safety and immunogenicity of each component are maintained when given at the same visit.
- Brand names
- PentaximPentavac
- Other names
- DTaP-IPV-Hib + MenACYW-TT
02
Targets
Diphtheria toxinNeuraminidasePertussis toxin and Bordetella pertussis adhesin antigensGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + pertussis vaccine + poliomyelitis vaccine + haemophilus influenzae type b conjugate vaccine + meningococcal (groups A, C, Y, W) conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + pertussis vaccine + poliomyelitis vaccine + haemophilus influenzae type b conjugate vaccine + meningococcal (groups A, C, Y, W) conjugate vaccine.